David Purselle
Psychiatry · Atlanta, GANPI 1356384135
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $198,892 of the $307,271 with a category attached, or 64.7%. 24 manufacturers reported payments, led by AbbVie at 35.2% of the total. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 726 payments — averaging $423.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$108K
- Supernus Pharmaceuticals, Inc.$62K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$60K
- Axsome Therapeutics, Inc.$22K
- Brainsway USA Inc$16K
- Vanda Pharmaceuticals Inc.$12K
- plus $28K from 18 others
Across 870 payments — averaging $8121.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2.5M
- AbbVie$1.8M
- Sage Therapeutics, LLC$629K
- Sumitomo Pharma America, Inc.$382K
- Boehringer Ingelheim$375K
- Teva Pharmaceuticals USA, Inc.$369K
- plus $999K from 18 others
What the payments were for
- Consulting fees$72,27224%
- Speaking & faculty fees$198,89265%
- Travel & lodging$22,9747%
- Food & beverage$13,0334%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 187 | $108,147 |
| Supernus Pharmaceuticals, Inc. | 112 | $62,010 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 61 | $59,701 |
| Axsome Therapeutics, Inc. | 17 | $21,542 |
| Brainsway USA Inc | 6 | $15,893 |
| Vanda Pharmaceuticals Inc. | 38 | $11,598 |
| Johnson & Johnson | 26 | $8,626 |
| Idorsia Pharmaceuticals US Inc | 7 | $6,595 |
| Otsuka America Pharmaceutical, Inc. | 46 | $5,268 |
| Neurocrine Biosciences, Inc. | 13 | $2,151 |
| Boehringer Ingelheim | 12 | $1,881 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,062 |
| Lundbeck LLC | 42 | $808 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $408 |
| Sunovion Pharmaceuticals Inc. | 15 | $271 |
| Tris Pharma Inc | 14 | $259 |
| Corium, LLC | 12 | $196 |
| Avanir Pharmaceuticals, Inc. | 4 | $187 |
| Noven Therapeutics, LLC | 9 | $156 |
| Eisai Inc. | 9 | $155 |
| Bausch Health US, LLC | 9 | $146 |
| Alkermes, Inc. | 7 | $140 |
| E.r. Squibb & Sons, L.L.C. | 2 | $57 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$105,636
- QELBREE$60,265
- REXULTI$53,606
- Auvelity$21,267
- Brainsway Deep TMS$15,740
- Fanapt$10,967
- SPRAVATO$8,080
- QUVIVIQ$6,429
- ABILIFY MAINTENA$713
- ABILIFY MYCITE$175
How this compares
$307,271 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 16 | $10,330 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $279 |
| Trazodone Hcl | 17 | $264 |
| Quetiapine Fumarate | 17 | $249 |
| Clonazepam | 34 | $127 |
| Alprazolam | 27 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $408 | $10,33016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Ray HorwitzAtlanta$64K
- Boadie DunlopAtlanta$61K
- Zohaib HaqueAtlanta$49K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
- Dwight OwensAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.